RU2006142896A - Замещенные енаминоны, их производные и их применение - Google Patents
Замещенные енаминоны, их производные и их применение Download PDFInfo
- Publication number
- RU2006142896A RU2006142896A RU2006142896/04A RU2006142896A RU2006142896A RU 2006142896 A RU2006142896 A RU 2006142896A RU 2006142896/04 A RU2006142896/04 A RU 2006142896/04A RU 2006142896 A RU2006142896 A RU 2006142896A RU 2006142896 A RU2006142896 A RU 2006142896A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- substituted
- unsubstituted
- aryl
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 claims abstract 112
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 95
- 229910052736 halogen Inorganic materials 0.000 claims abstract 74
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 73
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 58
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 53
- 239000001257 hydrogen Substances 0.000 claims abstract 53
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 43
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 38
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 32
- 150000001875 compounds Chemical class 0.000 claims abstract 32
- 150000003839 salts Chemical class 0.000 claims abstract 23
- 229940002612 prodrug Drugs 0.000 claims abstract 22
- 239000000651 prodrug Substances 0.000 claims abstract 22
- -1 chloro, bromo, iodo Chemical group 0.000 claims abstract 18
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 16
- 239000012453 solvate Substances 0.000 claims abstract 11
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 6
- LYZXOUIBNOGUCB-UHFFFAOYSA-N 1-(2,4-dichloro-5-fluorophenyl)-2-[(2,4-difluoroanilino)methylidene]pentane-1,3-dione Chemical compound C=1C(F)=C(Cl)C=C(Cl)C=1C(=O)C(C(=O)CC)=CNC1=CC=C(F)C=C1F LYZXOUIBNOGUCB-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 170
- 150000002367 halogens Chemical class 0.000 claims 71
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 59
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 35
- 150000002431 hydrogen Chemical class 0.000 claims 32
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims 31
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 28
- 125000003277 amino group Chemical group 0.000 claims 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- 125000004149 thio group Chemical group *S* 0.000 claims 27
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 26
- 125000004104 aryloxy group Chemical group 0.000 claims 26
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 26
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 26
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 26
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 26
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 26
- 238000000034 method Methods 0.000 claims 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 20
- 208000015114 central nervous system disease Diseases 0.000 claims 11
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- XGLHZTBDUXXHOM-WMZJFQQLSA-N 1-[(z)-2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(/Cl)=C/N1C=NC=N1 XGLHZTBDUXXHOM-WMZJFQQLSA-N 0.000 claims 1
- PULIYOGSPNXUJG-UHFFFAOYSA-N 2-(2-chlorobenzoyl)-3-(4-cyanoanilino)-n-ethylprop-2-enamide Chemical compound C=1C=CC=C(Cl)C=1C(=O)C(C(=O)NCC)=CNC1=CC=C(C#N)C=C1 PULIYOGSPNXUJG-UHFFFAOYSA-N 0.000 claims 1
- VNFHKLZFPHDSOC-UHFFFAOYSA-N 2-(2-chlorobenzoyl)-3-(4-cyanoanilino)-n-propylprop-2-enamide Chemical compound C=1C=CC=C(Cl)C=1C(=O)C(C(=O)NCCC)=CNC1=CC=C(C#N)C=C1 VNFHKLZFPHDSOC-UHFFFAOYSA-N 0.000 claims 1
- MSFPCACOZLJKPW-UHFFFAOYSA-N 2-(2-chlorobenzoyl)-n-ethyl-3-(4-iodoanilino)prop-2-enamide Chemical compound C=1C=CC=C(Cl)C=1C(=O)C(C(=O)NCC)=CNC1=CC=C(I)C=C1 MSFPCACOZLJKPW-UHFFFAOYSA-N 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- USOXBMZFVFXTDW-UHFFFAOYSA-N 3-(4-cyanoanilino)-2-(2-methylbenzoyl)-n-propylprop-2-enamide Chemical compound C=1C=CC=C(C)C=1C(=O)C(C(=O)NCCC)=CNC1=CC=C(C#N)C=C1 USOXBMZFVFXTDW-UHFFFAOYSA-N 0.000 claims 1
- ZVKLQQRYCUNZEV-UHFFFAOYSA-N 3-(4-ethynylanilino)-2-(2-methylbenzoyl)-n-propylprop-2-enamide Chemical compound C=1C=CC=C(C)C=1C(=O)C(C(=O)NCCC)=CNC1=CC=C(C#C)C=C1 ZVKLQQRYCUNZEV-UHFFFAOYSA-N 0.000 claims 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 102000005915 GABA Receptors Human genes 0.000 claims 1
- 108010005551 GABA Receptors Proteins 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 claims 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229950004164 loreclezole Drugs 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- LVVNZCAQYMFSSK-UHFFFAOYSA-N ethyl 3-(benzylamino)-2-(2-chlorobenzoyl)prop-2-enoate Chemical compound C=1C=CC=C(Cl)C=1C(=O)C(C(=O)OCC)=CNCC1=CC=CC=C1 LVVNZCAQYMFSSK-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/22—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56946504P | 2004-05-06 | 2004-05-06 | |
| US60/569,465 | 2004-05-06 | ||
| PCT/US2005/015869 WO2005108347A2 (en) | 2004-05-06 | 2005-05-05 | Substituted enaminones, their derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006142896A true RU2006142896A (ru) | 2008-06-20 |
Family
ID=35320783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006142896/04A RU2006142896A (ru) | 2004-05-06 | 2005-05-05 | Замещенные енаминоны, их производные и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7825278B2 (enExample) |
| EP (1) | EP1742904B1 (enExample) |
| JP (1) | JP5002452B2 (enExample) |
| CN (1) | CN1976892A (enExample) |
| AU (1) | AU2005240657A1 (enExample) |
| BR (1) | BRPI0510715A (enExample) |
| CA (1) | CA2565627A1 (enExample) |
| IL (1) | IL179068A0 (enExample) |
| MX (1) | MXPA06012839A (enExample) |
| NO (1) | NO20065595L (enExample) |
| RU (1) | RU2006142896A (enExample) |
| UA (1) | UA85711C2 (enExample) |
| WO (1) | WO2005108347A2 (enExample) |
| ZA (1) | ZA200609924B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138510A1 (en) * | 2005-06-17 | 2006-12-28 | The Regents Of The University Of California | Substituted enaminones as nicotinic acetylcholine receptor modulators |
| CA2695812A1 (en) | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| WO2009112459A1 (en) * | 2008-03-11 | 2009-09-17 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| CA2733499A1 (en) * | 2008-08-08 | 2010-02-11 | Neurosearch A/S | Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| PL2605652T3 (pl) | 2010-08-18 | 2018-04-30 | Samumed, Llc | Diketony i hydroksyketony jako aktywatory szlaku sygnalizacji kateninowej |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| PE20151721A1 (es) | 2013-02-22 | 2015-12-07 | Samumed Llc | Y-dicetonas como activadores de la ruta de senalizacion de wnt/b-catenina |
| KR102165385B1 (ko) | 2014-08-20 | 2020-10-15 | 사뮤메드, 엘엘씨 | 피부 노화 및 주름의 치료 및 예방을 위한 감마-디케톤 |
| AR115966A1 (es) | 2018-08-17 | 2021-03-17 | Pi Industries Ltd | Compuestos de fenilamidina y sus usos |
| CN111018734B (zh) * | 2019-12-13 | 2020-12-22 | 福建海西新药创制有限公司 | 一种盐酸西那卡塞中间体的合成方法 |
| CN113354530B (zh) * | 2020-03-07 | 2025-11-18 | 东莞市东阳光动物保健药品有限公司 | 一种制备4-乙酰基-1-萘甲酸的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| FR2639636B1 (fr) | 1988-11-30 | 1994-03-04 | Novapharme | Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant |
| US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| KR930703292A (ko) * | 1991-12-27 | 1993-11-29 | 쿠사이 요시히로 | 신규 퀴놀론 유도체 또는 그의 염 및 이 화합물을 함유하는 항균제 |
| ES2049640B1 (es) * | 1992-06-18 | 1994-12-16 | Genesis Para La Investigacion | Procedimiento paras la preparacion de acidos quinolin carboxilicos. |
| US5622967A (en) * | 1993-04-26 | 1997-04-22 | Sterling Winthrop, Inc. | Quinolone carboxamide Calpain inhibitors |
| TW273551B (enExample) * | 1993-05-24 | 1996-04-01 | Wakiei Seiyaku Kk | |
| GB9706730D0 (en) * | 1997-04-03 | 1997-05-21 | Pharmacia & Upjohn Spa | 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives |
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| MXPA04011156A (es) * | 2002-05-14 | 2005-02-17 | Univ California | Acidos quinoloncarboxilicos sustituidos, sus derivados, sitio de accion y usos de los mismos. |
-
2005
- 2005-05-05 US US11/123,597 patent/US7825278B2/en not_active Expired - Fee Related
- 2005-05-05 JP JP2007511639A patent/JP5002452B2/ja not_active Expired - Fee Related
- 2005-05-05 CA CA002565627A patent/CA2565627A1/en not_active Abandoned
- 2005-05-05 MX MXPA06012839A patent/MXPA06012839A/es unknown
- 2005-05-05 BR BRPI0510715-6A patent/BRPI0510715A/pt not_active IP Right Cessation
- 2005-05-05 EP EP05750643A patent/EP1742904B1/en not_active Expired - Lifetime
- 2005-05-05 UA UAA200612755A patent/UA85711C2/ru unknown
- 2005-05-05 CN CNA2005800214141A patent/CN1976892A/zh active Pending
- 2005-05-05 RU RU2006142896/04A patent/RU2006142896A/ru not_active Application Discontinuation
- 2005-05-05 AU AU2005240657A patent/AU2005240657A1/en not_active Abandoned
- 2005-05-05 ZA ZA200609924A patent/ZA200609924B/xx unknown
- 2005-05-05 WO PCT/US2005/015869 patent/WO2005108347A2/en not_active Ceased
-
2006
- 2006-11-06 IL IL179068A patent/IL179068A0/en unknown
- 2006-12-05 NO NO20065595A patent/NO20065595L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005240657A1 (en) | 2005-11-17 |
| EP1742904B1 (en) | 2012-10-31 |
| EP1742904A2 (en) | 2007-01-17 |
| US7825278B2 (en) | 2010-11-02 |
| JP2007536262A (ja) | 2007-12-13 |
| IL179068A0 (en) | 2007-03-08 |
| JP5002452B2 (ja) | 2012-08-15 |
| MXPA06012839A (es) | 2007-02-15 |
| CN1976892A (zh) | 2007-06-06 |
| NO20065595L (no) | 2007-02-02 |
| EP1742904A4 (en) | 2007-04-18 |
| WO2005108347A2 (en) | 2005-11-17 |
| BRPI0510715A (pt) | 2007-11-20 |
| WO2005108347A3 (en) | 2006-07-06 |
| US20080064748A1 (en) | 2008-03-13 |
| ZA200609924B (en) | 2008-12-31 |
| CA2565627A1 (en) | 2005-11-17 |
| UA85711C2 (ru) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003105900A (ru) | Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью | |
| RU2006142896A (ru) | Замещенные енаминоны, их производные и их применение | |
| RU2011103234A (ru) | Новые фенилпиразиноны в качестве ингибиторов киназы | |
| JP2018505898A5 (enExample) | ||
| RU2336267C2 (ru) | Производные пирролидона в качестве ингибиторов маов | |
| RU2008111991A (ru) | Органические соединения | |
| CA2565812A1 (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| JP2005527593A5 (enExample) | ||
| CA2441565A1 (en) | Bisarylamines as potassium channel openers | |
| RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
| UA80841C2 (en) | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) | |
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| SE0202134D0 (sv) | Therapeutic agents | |
| JP2005535592A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| RU2009106461A (ru) | Хинолиновые производные | |
| CA2505195A1 (en) | Quinazolinones as potassium channel modulators | |
| RU2015101532A (ru) | Замещенные бициклические алкокси-пиразольные аналоги в качестве аллостерических модуляторов рецепторов mglur5 | |
| RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
| RU2016140266A (ru) | Спироциклические аминовые производные в качестве модуляторов s1p | |
| JP2015516429A5 (enExample) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| DE602004031722D1 (de) | Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden | |
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100219 |